Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis

Introduction: Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies h...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Genta Uchida, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Eri Ishikawa, Kazuhiro Furukawa, Tadashi Iida, Yasuyuki Mizutani, Kentaro Yamao, Takuya Ishikawa, Yoji Ishizu, Takashi Honda, Masatoshi Ishigami, Hiroki Kawashima
Format:	Artigo
Jezik:	Inglês
Izdano:	Karger Publishers 2023-06-01
Serija:	Inflammatory Intestinal Diseases
Teme:	real-world evidence ustekinumab ulcerative colitis effectiveness risk factor
Online dostop:	https://beta.karger.com/Article/FullText/531497
Oznake:	Označite Brez oznak, prvi označite!